Creating viral nanoparticles to enhance cancer immunotherapy for ovarian cancer

Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies

NIH-funded research University of California, San Diego · NIH-11079607

This study is looking at new ways to use tiny viral particles to help improve treatments for ovarian cancer by boosting the immune system and changing the environment around tumors, which could lead to better results for patients.

Quick facts

Grant typeCareer grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Diego NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-11079607 on NIH RePORTER

What this research studies

This research focuses on developing innovative nanomedicines using viral nanoparticles to improve treatment outcomes for ovarian cancer. By bioengineering these nanoparticles to target and reprogram the tumor microenvironment, the research aims to enhance the effectiveness of cancer immunotherapy. The approach involves utilizing specific viral structures that can activate the immune system and convert the suppressive environment surrounding tumors, potentially leading to better responses in patients. The study will explore the use of Toll-like receptor agonists to stimulate the immune system and improve the overall efficacy of treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who have not responded adequately to standard treatments.

Not a fit: Patients with early-stage ovarian cancer or those who have not yet undergone any treatment may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective immunotherapy options for ovarian cancer patients, potentially improving survival rates and quality of life.

How similar studies have performed: Previous research has shown promise in using viral nanoparticles for cancer treatment, indicating potential for success in this novel approach.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanti-cancer therapyanticancer immunotherapy
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.